Oncolytics Biotech
ONCY
36 hedge funds and large institutions have $1.5M invested in Oncolytics Biotech in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 14 closing their positions.
5.45% less ownership
Funds ownership: 7.33% → 1.87% (-5.5%)
18% less funds holding
Funds holding: 44 → 36 (-8)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
79% less capital invested
Capital invested by funds: $7.26M → $1.5M (-$5.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$93.4K |
| 2 |
VF
Virtu Financial
New York
|
+$58K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$54.6K |
| 4 |
PI
PFG Investments
Woodbury,
New York
|
+$11.7K |
| 5 |
AI
Atom Investors
Austin,
Texas
|
+$11.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$5.15M |
| 2 |
ARC
Advisor Resource Council
Dallas,
Texas
|
-$135K |
| 3 |
Morgan Stanley
New York
|
-$128K |
| 4 |
Millennium Management
New York
|
-$97.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$40.9K |
ONCY Hedge Fund Activity: Q1 2024 in Review
36 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q1 2024, worth a combined $1.5M — down 79% from $7.26M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ONCY and 7 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 7 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $93.4K. The largest seller was Anson Funds Management, exiting entirely with an estimated $5.15M sold.
- 36 institutional investors held Oncolytics Biotech (ONCY) as of Q1 2024, down from 44 in Q4 2023.
- Funds reported $1.5M of Oncolytics Biotech stock for Q1 2024, down 79% quarter-over-quarter.
- 7 funds opened new Oncolytics Biotech positions in Q1 2024 and 14 closed out, a net change of -7 holders.
- The largest Oncolytics Biotech buyer in Q1 2024 was Goldman Sachs, an estimated $93.4K added.
- The largest Oncolytics Biotech seller in Q1 2024 was Anson Funds Management, an estimated $5.15M sold.
Based on aggregated 13F filings for Q1 2024.